Clinical practice guideline of BRCA1/2 testing for patients with breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guideline 2021

Breast cancer is the most common female cancer around the world. Approximately 5% to 10% of breast cancer is associated with a hereditary predisposition from inherited germline mutations, with about 15% of mutations occurring in the breast cancer susceptibility genes (BRCA1/2). Individuals carrying BRCA1/2 mutations may reduce their risk of breast cancer through screening and preventing managements. It is essential for breast oncologists to improve their ability of identifying individuals with high risk of BRCA1/2 mutations, providing reasonable genetic counselling guidance to high risk individuals. Chinese Society of Breast Surgery (CSBrS) evaluated the relevant evidences using the Grading of Recommendations Assessment, Development, and Evaluation system, and developed the Clinical Practice Guideline of BRCA1/2 Testing for Patients with Breast Cancer (Version 2021), with the aim of providing guidance to the clinical practices of breast surgeons in China.

• Publication year

  2021

• Venue

  Chinese Medical Journal

• Publication date

  2021-06-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/CM9.0000000000001587PMID 34091527PMCID 8280056
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical practice guidelines for sentinel lymph node biopsy in patients with early-stage breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021

  2021cited by this paper
• Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.

  2020influential reference
• Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons

  2019cited by this paper
• Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening.

  2016cited by this paper
• Hereditary breast and ovarian cancer: new genes in confined pathways

  2016cited by this paper
• Comparison of Nodal Metastasis Between BRCA Mutation Carriers and Non-BRCA Mutation Carriers with Breast Cancer

  2014cited by this paper
• Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes

  2014cited by this paper
• Extended Indications for Nipple‐Sparing Mastectomy

  2011influential reference
• Nipple-sparing mastectomy: where are we now?

  2008influential reference
• National Surgical Adjuvant Breast and Bowel Project

  2005cited by this paper
• Breast and ovarian cancer.

  2003cited by this paper
• Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.

  2002cited by this paper
• Hereditary breast cancer.

  1998cited by this paper

• Application of genetic testing criteria for hereditary breast cancer in South Africa

  2025cites this paper
• BRCA mutation status and pathological characterization of breast cancer in Zhoushan Islands, China

  2024cites this paper
• Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline

  2024cites this paper
• Multigenic panels in breast cancer: clinical utility and management of patients with pathogenic variants other than BRCA1/2.

  2024cites this paper
• Chinese Society of Breast Surgery (CSBrS) Practice Guideline 2022

  2023cites this paper
• Overview on population screening for carriers with germline BRCA mutation in China

  2022cites this paper
• Clinical practice guidelines for risk assessment to identify women at high risk of breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021

  2021cites this paper